Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centre For Translational Stem Cell Biology Limited currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, indicating a highly concentrated prosecution effort. The presence of 1 pending action suggests that the company's current patent strategy is focused on a specific technical advancement rather than a large-scale filing campaign. This singular focus allows the applicant to concentrate its resources on resolving the issues raised in this one case.
The entirety of the pending workload is located within 1 distinct art unit, which centralizes the company's interactions with the patent office. ALAM, DANYAL HASSAN serves as the busiest examiner for the portfolio, currently handling 1 pending office action. Because this examiner is responsible for the assigned matter, they manage the total volume of the company's current office action responses. This arrangement means that the success of the current prosecution cycle depends entirely on the specific feedback and requirements issued by this single examiner in the pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18345934 | STEM CELL COMPOSITIONS FOR CULTURING CORONAVIRUSES AND METHODS OF MAKING AND USING THEREOF | ALAM, DANYAL HASSAN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18345934 | STEM CELL COMPOSITIONS FOR CULTURING CORONAVIRUSES AND METHODS OF MAKING AND USING THEREOF | ALAM, DANYAL HASSAN | 1672 | §101§103§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentre For Translational Stem Cell Biology Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Danyal Hassan Alam has the most, with 1 of Centre For Translational Stem Cell Biology Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
